title: Blood substitutes based on nanobiotechnology.
abstract: Stimulated by concerns of potential infective agents in donated blood, commercial enterprises have attempted to develop blood substitutes since the 1900s. After several years of development, a few of the many leads are showing promise. In this article, nanobiotechnological approaches that are now in phase III clinical trials are reviewed, followed by a discussion of how important basic knowledge gained is being used to develop new generations of blood substitutes based on nanobiotechnology.
authors.affiliation: Department of Physiology, Faculty of Medicine, McGill University, 3655 Drummond Street, Montreal, Quebec, H3G 1Y6, Canada. artcell.med@mcgill.ca
authors.forename: Thomas Ming Swi
authors.initials: TM
authors.lastname: Chang
mesh_terms: D000818:Animals; D040761:Biomimetic Materials / Q000737:chemistry* / Q000627:therapeutic use*; D001709:Biotechnology / Q000639:trends*; D001802:Blood Substitutes / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D036103:Nanotechnology / Q000639:trends*
chemical_list: D001802:Blood Substitutes